Disease severity-associated gene expression in canine myxomatous mitral valve disease is dominated by TGFß signalling

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Myxomatous mitral valve disease (MMVD) is the most common acquired canine cardiovascular disease and shares many similarities with human mitral valvulopathies. While transcriptomic datasets are available for the end-stage disease in both species, there is no information on how gene expression changes as the disease progresses, such that it cannot be stated with certainty if the changes seen in end-stage disease are casual or consequential. In contrast to humans, the disease in dogs can be more readily examined as it progresses, and this allows an opportunity for insight into disease pathogenesis relevant to both species. The aim of this study was to identify changes in valve gene expression as canine MMVD advances over an entire life-time, from normal (grade 0) to severely affected (grade 4), and differences in gene expression comparing normal and disease areas of the same valve. Transcriptomic profiling identified 1002 differentially expressed genes (DEGs) across all four disease grades when compared with normal valves with the greatest number of DEGs in grade 3 (673) and grade 4 (507). DEGs were associated with a large number of gene families, including genes encoding cytoskeletal filaments, peptidases, extra-cellular matrix (ECM) proteins, chemokines and integrins. Gene enrichment analysis identified significant grade-dependent changes in gene clustering, with clusters trending both up and down as disease progressed. Significant grade-dependent changes in hallmark disease gene expression intensity were identified, including ACTA2, HTR2B, MMP12 and CDKN2A. Gene Ontology terms were dominated by terms for ECM and inflammation with TGFβ1, TNF, IFGN identified as the top up-stream regulators in both whole and dissected diseased valve samples. These data show that while disease progression in MMVD is associated with increasing numbers of DEGs, TGFβ appears to be the dominant signalling pathway controlling pathogenesis irrespective of disease severity
Original languageEnglish
JournalFrontiers in Genetics
Early online date27 Apr 2020
Publication statusE-pub ahead of print - 27 Apr 2020

Keywords / Materials (for Non-textual outputs)

  • myxomatous mitral valve disease
  • gene expression
  • canine
  • transforming growth factor β


Dive into the research topics of 'Disease severity-associated gene expression in canine myxomatous mitral valve disease is dominated by TGFß signalling'. Together they form a unique fingerprint.

Cite this